On 2 November 2026, Ribomic disclosed the monthly exercise status of the Series 19 stock acquisition rights it issued by way of a third-party allotment, with terms allowing the exercise price to be revised. The report outlines the terms of the rights and the key points in the monthly exercise trends.
Ribomic issued Series 19 stock acquisition rights by way of a third-party allotment. The stock acquisition rights include terms allowing the exercise price to be revised.
The disclosure was made on 2 November 2026, providing an overview of the monthly exercise status through timely disclosure.
Specific monthly exercise figures and timing details are provided in the article, while further disclosure on future developments is awaited.